BCL2 and acute myeloid leukemia: The DNA hypomethylating agent azacytidine, in combination with the BCL-2 inhibitor venetoclax, suppresses Complex II activity by reducing sdhA glutathionylation, which inhibits OXPHOS activity in acute myeloid leukemia stem cells (AML LSCs).